NCT01123564

Efficacy and Safety of Lucentis for Clinically Significant Macular Edema Secondary to Central Retinal Vein Occlusion

A Randomized, Controlled, Two-center Phase II Study Assessing the Efficacy and Safety of Intravitreal Lucentis Injections in Patients With Clinically Significant Macular Edema Secondary to Central Retinal Vein Occlusion

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: University of Pecs · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study aims to assess if Lucentis injection applied into the eye is superior to conventional treatment concerning the prevention of visual loss in patients having clinically significant macular edema secondary to retinal vein occlusion

Conditions

• Retinal Vein Occlusion
• Macular Edema

Interventions

Type	Name	Description
DRUG	ranibizumab	applied monthly in the first 3 months period, and after this only if visual acuity (VA) decreases with more than 5 letters at any monthly visits
RADIATION	Argon laser treatment	Conventional grid pattern argon laser treatment and panretinal argon laser photocoagulation in an as needed basis.

Timeline

• Start date: 2009-08-01
• Primary completion: 2011-09-01
• Completion: 2011-09-01
• First posted: 2010-05-14
• Last updated: 2010-05-14

Locations

2 sites across 1 country: Hungary